The present invention relates to a lithium secondary battery including an electrolyte including a non-aqueous organic solvent, a lithium salt and an additive comprising a compound represented by Chemical Formula 1; and a battery case in which the electrolyte is housed, wherein the battery case has a shape with a width (W), a height (H), and a thickness (Th), when a maximum value among the width (W), the height (H), and the thickness (Th) is a and a minimum value among the width (W), the height (H), and the thickness (Th) is b, b/a is 0.01 or more:

##STR00001## wherein, in Chemical Formula 1, A is a substituted or unsubstituted aliphatic chain or (C.sub.2H.sub.4OC.sub.2H.sub.4-)n, and n is an integer from 1 to 10.

The present invention relates to a lithium secondary battery including a positive electrode including a positive active material, the positive active material including a nickel-containing lithium transition metal compound; a negative electrode including a negative active material; and an electrolyte including a non-aqueous organic solvent, a lithium salt, and an additive comprising a compound represented by Chemical Formula 1, wherein the content of Ni is 60 mol % or more based on 100 mol % of the total transition metals in the lithium transition metal compound.

##STR00001## wherein, in Chemical Formula 1, A is a substituted or unsubstituted aliphatic chain or (C.sub.2H.sub.4OC.sub.2H.sub.4-)n, and n is an integer from 1 to 10.

A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): ##STR00001## wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.

The present invention relates to the use of novel adducts of general formula (I) TPP.sub.xTPOP.sub.(1-x), wherein TPP is triphenylphosphine, TPOP is triphenylphosphite and x is a real number between 0.05 and 0.9. These novel adducts are useful for the bromination of primary alcohols, in particular for the bromination of primary alcohols.

Provided herein is technology relating to natural lipids containing non--oxidizable fatty acids and particularly, but not exclusively, to compositions and methods related to the production and use of natural lipids containing non--oxidizable fatty acids.

A medical lubricant may comprise a base oil. The medical lubricant can be used on a surgical device.

Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomer synthesis while maintaining overall yield and purity of a synthesized oligomer.

The process for producing a silyl phosphine compound of the present invention comprises a first step of mixing a solvent having a relative dielectric constant of not more than 4, a basic compound, a silylating agent and phosphine to obtain a solution containing a silyl phosphine compound, a second step of removing the solvent from the solution containing a silyl phosphine compound to obtain a concentrated solution of a silyl phosphine compound, and a third step of distilling the concentrated solution of a silyl phosphine compound to obtain the silyl phosphine compound. The silyl phosphine compound of the present invention is a silyl phosphine compound represented by the following general formula (1), wherein a content of a compound represented by the following general formula (2) is not more than 0.5 mol %. (For explanatory notes of the formulas, see the specification.)

A non-aqueous electrolyte for a lithium-ion battery and a lithium-ion battery. The non-aqueous electrolyte comprises unsaturated phosphate compounds and unsaturated cyclic carboxylic acid anhydride compounds. The unsaturated phosphate compounds have the structure illustrated in structural formula 4; structural formula 4: R.sub.13, R.sub.11, and R.sub.12 are independently selected from hydrocarbon groups having 1-5 carbon atoms respectively, and at least one of R.sub.13, R.sub.11, and R.sub.12 is an unsaturated hydrocarbon group containing double bonds or triple bonds; the unsaturated cyclic carboxylic acid anhydride compounds have the structure illustrated in structural formula 5; structural formula 5: R.sub.14 is independently selected from vinylidene having 2-4 carbon atoms or fluoro-substituted vinylidene. By means of the synergistic effect of two compounds, the non-aqueous electrolyte has excellent high-temperature cycling performance and storage performance, and also has lower impedance and good low-temperature performance.

##STR00001##

This invention relates to novel pyrido[2,3-d]pyrimidinones of Formula I:

##STR00001##

and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CDK-4 and/or CDK-6 inhibitor.